Price T Rowe Associates Inc Kymera Therapeutics, Inc. Transaction History
Price T Rowe Associates Inc
- $869 Billion
- Q3 2024
A detailed history of Price T Rowe Associates Inc transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 6,645,474 shares of KYMR stock, worth $293 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
6,645,474
Previous 6,390,658
3.99%
Holding current value
$293 Million
Previous $191 Million
64.88%
% of portfolio
0.04%
Previous 0.02%
Shares
16 transactions
Others Institutions Holding KYMR
# of Institutions
184Shares Held
64.4MCall Options Held
50.6KPut Options Held
81.7K-
Baker Bros. Advisors LP New York, NY6MShares$264 Million3.04% of portfolio
-
Bvf Inc San Francisco, CA5.16MShares$227 Million7.77% of portfolio
-
Atlas Venture Life Science Advisors, LLC4.9MShares$216 Million28.59% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.75MShares$209 Million0.0% of portfolio
-
Wellington Management Group LLP Boston, MA4.62MShares$203 Million0.04% of portfolio
About Kymera Therapeutics, Inc.
- Ticker KYMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 54,705,800
- Market Cap $2.41B
- Description
- Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...